Skip to main content

nvo

3 articles found

NVO: GLP-1 Giant Falls to 10x Earnings on Lilly Fears

Novo Nordisk shares have collapsed to $37.45, a 59% decline from their 52-week high of $91.90, after the company's next-generation obesity drug CagriSema delivered clinical trial results that trailed Eli Lilly's Zepbound. The February 27 selloff alone erased 21% of the stock's value in a single session, marking the most dramatic repudiation of a GLP-1 leader since the obesity drug revolution began. At 10.3 times trailing earnings, Novo Nordisk now trades at a valuation that would be cheap for a utility company — let alone a pharmaceutical giant that generated DKK 308 billion ($44 billion) in revenue last year with 81% gross margins. The market cap has contracted to $166.5 billion, roughly half of where it stood six months ago. The question facing investors is whether the CagriSema disappointment is a fundamental thesis-breaker or whether the market has overreacted. Novo Nordisk still dominates the GLP-1 market alongside Eli Lilly, with Wegovy and Ozempic generating massive cash flows. But with the company guiding for a 5–13% decline in 2026 sales due to U.S. price compression, the near-term outlook is genuinely challenging. For context on how NVO reached this point, see our [earlier analysis of the 50% price reduction](/articles/nvo-analysis-novo-nordisks-50-price-slash-creates-a-deep-value-puzzle-for-glp-1-investors) that preceded this latest crash.

NVONovo NordiskGLP-1

NVO: Novo Nordisk's 50% Price Slash Creates a Deep-Value

Novo Nordisk (NVO) has gone from the world's most valuable healthcare company to a deep-value opportunity in the span of twelve months. Shares closed at $38.16 on February 25, 2026 — down 59% from their 52-week high of $93.80 and trading at just 10.5x trailing earnings. The Danish pharmaceutical giant hit a fresh 52-week low of $37.65 during today's session on volume 2.6 times the daily average, as investors digested the company's announcement that it will cut U.S. list prices on Ozempic and Wegovy by up to 50% starting in 2027. The price cuts represent a strategic pivot that could reshape the entire GLP-1 market. For years, Novo Nordisk and rival Eli Lilly have commanded premium pricing for their obesity and diabetes drugs — Ozempic and Wegovy carry U.S. list prices above $1,000 per month. By voluntarily halving prices, Novo is betting that volume gains from dramatically expanded insurance coverage and patient access will more than offset the per-unit revenue decline. It is a gamble that pits near-term margin compression against long-term market dominance. For investors, the question is straightforward: does a sub-11x P/E ratio adequately compensate for the margin headwinds ahead, or is the selloff a classic overreaction that creates a generational entry point into the world's dominant GLP-1 franchise? The answer lies in Novo's financial fundamentals, its competitive moat, and whether the company's massive manufacturing investments can deliver the scale needed to make lower prices profitable.

NVONovo NordiskOzempic

Novo Nordisk Crashes 47% From Peak as Obesity Drug Empire

Novo Nordisk, the Danish pharmaceutical giant that once seemed invincible atop the global obesity drug market, is now fighting on every front simultaneously — and investors are voting with their feet. Shares of Novo Nordisk (NVO) traded at $49.57 on Monday, down a staggering 47% from their 52-week high of $93.80, as the company grapples with intensifying competition from Eli Lilly, a legal war against compounding pharmacies, and a 2026 financial outlook that shocked Wall Street with the prospect of declining revenues. The scale of the reversal is remarkable. Just months ago, Novo was the most valuable company in Europe and the undisputed leader in GLP-1 weight loss treatments. Today, its market capitalization has been cut roughly in half to $220.4 billion, while rival Eli Lilly commands a valuation north of $932 billion — more than four times Novo's size. In the span of a single month, NVO shares plunged 21%, with a single-day drop of 14% followed by violent snapback rallies, as investors tried to parse whether the company's problems are temporary growing pains or signs of a structural decline. The catalyst for the latest rout was Novo's 2026 guidance, released alongside otherwise solid fourth-quarter results on February 4. While Q4 revenue came in at DKK 78.4 billion with a 34% net profit margin — numbers most companies would celebrate — the forward outlook told a different story entirely. On an adjusted basis, Novo expects sales and operating profit to decline 5% to 13% at constant exchange rates in 2026, a dramatic contrast to Eli Lilly's guidance calling for 25% sales growth in the same period.

Novo NordiskNVOEli Lilly